
Analytics and Upstream Process Design for mRNA Synthesis
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, explains how capping is measured for mRNA synthesis and how upstream process design shapes downstream purity.
PharmTech spoke with Marco Pupo, PhD, innovation and development coordinator at Anemocyte, a biotech manufacturing organization that specializes in the contract development and manufacturing of plasmids, about the most appropriate analytical technologies to use in messenger RNA (mRNA) analysis and how decisions made during upstream processing impacts downstream processing. Anemocyte won the CPHI Award for Manufacturing Excellence at CPHI Milan 2026 in October for the company’s one-pot technology for messenger RNA (mRNA) synthesis, AMCAP.
On analytics, Pupo identifies liquid chromatography coupled to mass spectrometry as the gold standard for capping quantification. The method cleaves a short fragment from the 5′ end of the mRNA and resolves Cap0, Cap1, and uncapped structures, he explains. Its drawbacks, however, are cost and the need for highly skilled analysts. The alternatives each carry limitations. Capillary electrophoresis cannot resolve a single methyl group, so it cannot distinguish Cap0 from Cap1, according to Pupo. Standard enzymatic assays report capped versus uncapped mRNA but cannot discriminate between the 2 capped structures. Despite its expense, Pupo maintains that mass spectrometry remains the method of choice.
For process design, he argues that minimizing upstream steps is the most effective way to limit contaminants, such as double-stranded RNA, residual enzymes and reagents, and unincorporated nucleotides. Nucleocapsid protein (NCAP) reduced the number of upstream steps in mRNA synthesis, and the team at Anemocyte designed a buffer with reaction conditions that suppress double-stranded RNA formation, helped by salt concentration and the use of a low double-strand polymerase.
A streamlined one-pot protocol also avoids repeated enzyme additions, which in turn limits residual enzyme and reagent accumulation and makes what remains easier to clear, says Pupo. Because capping and transcription are synchronized, consumption kinetics run more completely, lowering the risk of leftover free nucleotides, S-adenosylmethionine byproducts, and capping reagents.
For downstream clearance, several commercial options exist, most based on chromatography (eg, affinity or hydrophobic interaction) or filtration, with tangential flow filtration the most important. Pupo’s conclusion is that combining a strong one-pot upstream process such as AMCAP with a sound downstream method yields mRNA that is highly pure and almost entirely free of contaminants.
About the Speaker
Marco holds a background in Pharmaceutical Technology and Biochemistry, bringing over a decade of academic and industry experience in biotechnology R&D. He has successfully coordinated cross-functional teams in matrixed environments, overseeing international programs from proof-of-concept to GMP technology transfer. Marco specializes in process and analytical development for non-viral cell therapies, proteins, and nucleic acid-based therapeutics. An expert inventor in the RNA field, he has pioneered breakthrough single-pot and simultaneous co-transcriptional in vitro capping technologies (AMCAP™) to streamline scale-up and reduce manufacturing bottlenecks for therapeutic mRNA.
Related to this article








